by Biopharma buffers are solutions used to maintain and control pH during various biopharmaceutical product manufacturing processes such as cell-culture, purification, and final drug formulation. Buffers solutions help stabilize proteins and other sensitive biological molecules against changes in pH. Increasing investments in research and development of novel biologics, cell and gene therapy products are propelling demand for advanced biopharma buffers. The global Biopharma Buffer Market is estimated to be valued at US$ 4.24 Billion in 2024 and is expected to exhibit a CAGR of 11% over the forecast period 2024 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
Increasing investments in R&D of novel biologics and cell and gene therapy products is a key trend spurring growth of the biopharma buffer market. Biopharmaceutical manufacturers are investing heavily in developing advanced therapeutics such as monoclonal antibodies, vaccines, and regenerative medicines which require optimized buffer solutions. For instance, according to the Pharmaceutical Research and Manufacturers of America (PhRMA), the biopharmaceutical industry’s research and development investment grew from US$ 79.6 billion in 2015 to US$ 102.8 billion in 2020. Rising R&D expenditure is expected to propel the development of complex biologics requiring specialized buffer solutions, thus driving market growth over the forecast period.
SWOT Analysis
Strength: The Biopharma Buffer Market has high growth prospects owing to increasing investments in R&D for drug development and growing biologics industry.
Weakness: High costs associated with buffer formulations and regulation can hamper market growth.
Opportunity: Emerging markets in Asia Pacific offer lucrative opportunities for market expansion. Growing demand for biologics will also create growth opportunities.
Threats: Stringent regulatory approval process poses challenges. Substitution threat from alternatives also affects the market.
Key Takeaways
The Global Biopharma Buffer Market Share is expected to witness high growth at a CAGR of 11% during the forecast period of 2024 to 2030.
Regional analysis: The North America region currently dominates the Biopharma Buffer Market owing to growing biopharmaceutical industry and presence of major players. Asia Pacific is projected to be the fastest growing market due to increasing healthcare investments and expanding biotech sector in emerging countries.
Key players operating in the Biopharma Buffer Market are Digital Medics Pty. Ltd., Emperra GmbH E-Health Technologies, Novo Nordisk, Companion Medical Inc., Jiangsu Deflu Medical Device Co. Ltd., Medtronic PLC, Pendiq GmbH, Sanofi, Berlin Chemie Companion Medical Inc., Bigfoot Biomedical, Digital Medics Pty ltd, Eli Lilly and company, Ypsomed Holding AG, Diabnext Diamesco Co. Ltd.
